Gt biopharma reports first quarter fiscal 2022 financial results and business update

Brisbane, calif., may 16, 2022 (globe newswire) -- gt biopharma, inc. (the “company”) (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, today announced first quarter fiscal 2022 results for the period ended march 31, 2022.
GTBP Ratings Summary
GTBP Quant Ranking